grant
for
$255,990 to conduct research and development work on a novel dual-function therapeutic/vaccine product, designated as TheraVax™. TheraVax not only can block entry of SARS-CoV-2 but also can activate the immune system to produce effector T cells and neutralizing antibodies to eliminate SARS-CoV-2. This unique dual-function therapeutic/vaccine could work at an early stage of infection to prevent hospitalization and in mild or severe disease to block viral spread while activating appropriate immune responses.
NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering, said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremen